Eli Lilly and Company (NYSE:LLY) Shares Down 1.5% – Should You Sell?

Shares of Eli Lilly and Company (NYSE:LLY) traded down 1.5% on Monday . The stock traded as low as $988.88 and last traded at $995.6320. 3,044,939 shares were traded during trading, a decline of 25% from the average session volume of 4,041,901 shares. The stock had previously closed at $1,010.31.

Analysts Set New Price Targets

LLY has been the topic of several research analyst reports. Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $886.00 to $1,104.00 in a research note on Monday, November 10th. UBS Group raised their price target on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research note on Friday, November 7th. BMO Capital Markets set a $1,200.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, December 4th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Finally, Scotiabank assumed coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,109.24.

Eli Lilly and Company Stock Performance

The stock has a market capitalization of $939.25 billion, a price-to-earnings ratio of 48.61, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The company has a 50 day simple moving average of $931.98 and a 200-day simple moving average of $815.46. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the business earned $1.18 earnings per share. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Painted Porch Advisors LLC lifted its stake in Eli Lilly and Company by 125.7% during the 3rd quarter. Painted Porch Advisors LLC now owns 79 shares of the company’s stock valued at $60,000 after acquiring an additional 44 shares in the last quarter. Strategic Investment Solutions Inc. IL raised its holdings in shares of Eli Lilly and Company by 1.6% in the third quarter. Strategic Investment Solutions Inc. IL now owns 741 shares of the company’s stock valued at $565,000 after purchasing an additional 12 shares during the last quarter. Severin Investments LLC lifted its position in shares of Eli Lilly and Company by 19.1% during the third quarter. Severin Investments LLC now owns 680 shares of the company’s stock valued at $519,000 after purchasing an additional 109 shares in the last quarter. Allworth Financial LP lifted its position in shares of Eli Lilly and Company by 9.2% during the third quarter. Allworth Financial LP now owns 62,578 shares of the company’s stock valued at $47,747,000 after purchasing an additional 5,249 shares in the last quarter. Finally, IFP Advisors Inc boosted its holdings in Eli Lilly and Company by 13.2% during the third quarter. IFP Advisors Inc now owns 17,615 shares of the company’s stock worth $13,445,000 after purchasing an additional 2,057 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.